Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Mar 13:1:4.
doi: 10.1186/1750-1172-1-4.

Naxos disease: cardiocutaneous syndrome due to cell adhesion defect

Affiliations
Review

Naxos disease: cardiocutaneous syndrome due to cell adhesion defect

Nikos Protonotarios et al. Orphanet J Rare Dis. .

Abstract

Naxos disease is a recessively inherited condition with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) and a cutaneous phenotype, characterised by peculiar woolly hair and palmoplantar keratoderma. The disease was first described in families originating from the Greek island of Naxos. Moreover, affected families have been identified in other Aegean islands, Turkey, Israel and Saudi Arabia. A syndrome with the same cutaneous phenotype and predominantly left ventricular involvement has been described in families from India and Ecuador (Carvajal syndrome). Woolly hair appears from birth, palmoplantar keratoderma develop during the first year of life and cardiomyopathy is clinically manifested by adolescence with 100% penetrance. Patients present with syncope, sustained ventricular tachycardia or sudden death. Symptoms of right heart failure appear during the end stages of the disease. In the Carvajal variant the cardiomyopathy is clinically manifested during childhood leading more frequently to heart failure. Mutations in the genes encoding the desmosomal proteins plakoglobin and desmoplakin have been identified as the cause of Naxos disease. Defects in the linking sites of these proteins can interrupt the contiguous chain of cell adhesion, particularly under conditions of increased mechanical stress or stretch, leading to cell death, progressive loss of myocardium and fibro-fatty replacement. Implantation of an automatic cardioverter defibrillator is indicated for prevention of sudden cardiac death. Antiarrhythmic drugs are used for preventing recurrences of episodes of sustained ventricular tachycardia and classical pharmacological treatment for congestive heart failure, while heart transplantation is considered at the end stages.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cutaneous phenotype of Naxos disease: woolly hair (A), palmar (B) and plantar (C) keratoses.
Figure 2
Figure 2
Spontaneous sustained ventricular tachycardia originating from the right ventricular posterior wall, showing left bundle branch block configuration and superior axis.
Figure 3
Figure 3
Haematoxylin-eosin stained section from the right ventricular free wall of a patient with Naxos disease (surgical sample). There is extensive myocyte loss with fibrofatty replacement (magnification × 100).

References

    1. Protonotarios N, Tsatsopoulou A, Patsourakos P, Alexopoulos D, Gezerlis P, Simitsis S, Scampardonis G. Cardiac abnormalities in familial palmoplantar keratosis. Br Heart J. 1986;56:321–326. - PMC - PubMed
    1. Protonotarios N, Tsatsopoulou A, Scampardonis G. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;319:175. - PubMed
    1. Fontaine G, Protonotarios N, Tsatsopoulou A, Tsezana R, Fontaliran F, Frank R. Comparisons between Naxos disease and arrhythmogenic right ventricular dysplasia by electrocardiography and biopsy. Circulation. 1994;90:3233.
    1. Protonotarios N, Tsatsopoulou A. Arrhythmogenic right ventricular cardiomyopathy. Clinical forms of the disease. Hellenic J Cardiol. 1998;39:78–80.
    1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93:841–842. - PubMed

Publication types

MeSH terms